Agilent acquires ACEA Bioscience for $250M in cash
Agilent Technologie announced it has signed a definitive agreement to acquire privately-owned ACEA Biosciences Inc. , a developer of cutting-edge cell analysis instruments for life science research and clinical diagnostics, for $250M in cash. Since its inception in 2002, ACEA has launched two ground-breaking, highly differentiated platforms. ACEA is revolutionizing the field of flow cytometry with its high-performance, customizable line of NovoCyte benchtop flow cytometers. ACEA's xCELLigence instruments enable label-free, real-time monitoring of cell growth, cell function, and cellular responses to a variety of treatments, providing scientists information-rich cellular assays. ACEA also has a CFDA approved and CE-IVD labelled cytometer configuration. ACEA's clinical flow cytometer, currently commercialized primarily in China, brings a unique opportunity with Agilent's Reagent Partnership business within Agilent's Diagnostics and Genomics Group which provides reagents for flow cytometry. ACEA instruments are used worldwide in both academia and industry across a wide range of life science applications from basic research to clinical diagnostics including preclinical drug discovery and development, toxicology & safety pharmacology, and various disease studies.